Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 409 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar chris2ffer (62.66) Submitted: 5/26/2015 10:01:58 PM : Outperform Start Price: $110.34 GILD Score: +1.70

Alot of great drugs on the way

Recs

0
Member Avatar Dpomfool98 (< 20) Submitted: 5/25/2015 10:37:04 PM : Outperform Start Price: $110.84 GILD Score: +1.60

New products and acquisitions. Lots of cash.

Recs

0
Member Avatar dbet16 (< 20) Submitted: 5/23/2015 6:08:15 PM : Outperform Start Price: $111.09 GILD Score: +1.53

Outperform.....Great Co. fine balance sheet... Able to withstand most competition intrusions.

Recs

0
Member Avatar TMFPencils (99.83) Submitted: 5/13/2015 12:13:55 PM : Outperform Start Price: $106.39 GILD Score: +5.05

A cash flow machine trading at an arguably cheap P/FCF multiple of 14. Gilead produced $12.3 billion in FCF in 2014, with $10.1 billion of cash currently sitting on the balance sheet. The company's experienced management team has been timely with share buybacks and bought back $5.3 billion worth of shares in 2014. Outperform.

Recs

0
Member Avatar trizoll (67.85) Submitted: 5/11/2015 8:48:00 PM : Outperform Start Price: $104.21 GILD Score: +6.93

The company is flush with cash flow and will be looking for an acquisition to continue as the Hep C franchise slows down in a few years.

Recs

0
Member Avatar infiniteflow (61.10) Submitted: 5/9/2015 9:26:50 AM : Outperform Start Price: $104.19 GILD Score: +7.89

This is a weighing machine stock that ticks all the boxes - management, profitability, favorable macro conditions.

Recs

0
Member Avatar chessman777 (61.92) Submitted: 5/8/2015 12:44:02 PM : Outperform Start Price: $104.19 GILD Score: +7.89

solid company with a great pipeline

Recs

0
Member Avatar tradeseeker14 (25.10) Submitted: 5/5/2015 5:54:37 PM : Underperform Start Price: $103.20 GILD Score: -7.89

Way too easy to buy something is not right here

Recs

0
Member Avatar mptx44 (68.65) Submitted: 5/1/2015 9:30:14 AM : Outperform Start Price: $103.26 GILD Score: +7.91

GILD will have consistent earnings.

Recs

0
Member Avatar clangmead (33.64) Submitted: 5/1/2015 6:09:23 AM : Outperform Start Price: $103.20 GILD Score: +7.89

eod

Recs

0
Member Avatar Marty1985McFly (55.82) Submitted: 4/29/2015 4:16:50 PM : Outperform Start Price: $102.28 GILD Score: +9.06

The valuation just makes this on look like a no brainer.

Recs

0
Member Avatar sparkplug41 (< 20) Submitted: 4/21/2015 1:02:00 PM : Outperform Start Price: $104.84 GILD Score: +6.36

The technical analysis says strong buy and qualitatively people are saying good things.

Recs

0
Member Avatar SpartanMAC (< 20) Submitted: 4/20/2015 10:44:18 PM : Outperform Start Price: $101.42 GILD Score: +10.42

Top 30 with min market cap of 750M.

Recs

0
Member Avatar Mi888 (< 20) Submitted: 4/18/2015 11:53:50 AM : Outperform Start Price: $100.83 GILD Score: +10.59

Strong cash flows

Recs

0
Member Avatar WSMOOT19 (71.14) Submitted: 4/18/2015 12:22:38 AM : Outperform Start Price: $50.66 GILD Score: +85.25

Cheap Stock

Recs

0
Member Avatar dstwhit (79.27) Submitted: 4/17/2015 2:49:24 PM : Outperform Start Price: $101.00 GILD Score: +9.30

growing company in growing industyr, relatively low risk due to size and p/e (~13), CEO has 81% glassdoor approval (though only 2.8 rating for overall company); Tom E., Saul, and SA positive

Recs

0
Member Avatar samdcaek (49.85) Submitted: 4/16/2015 8:54:01 PM : Outperform Start Price: $102.35 GILD Score: +8.57

Lowest P/E of biotech horseman. Large increased cash flow in past year without a relevant increase in share price.

Recs

0
Member Avatar Herbstmd (59.09) Submitted: 4/11/2015 12:30:15 PM : Outperform Start Price: $102.01 GILD Score: +9.39

Major league player in bioPharm. Harvoni will be a great money maker, even with negation so downward. Too many people have Hep C. And there more than Harvoni.

Recs

1
Member Avatar TMFbelle (58.02) Submitted: 4/7/2015 11:39:52 AM : Outperform Start Price: $99.27 GILD Score: +11.73

This company has been on my watch list for a few months now. They are currently the leader when it comes to Hepatitis B medication which actually cures the disease with minimal doses (in comparison to other drugs/competitors in the market) also drugs are included heavily in almost all HIV treatment procedures. Patents for newer drugs wont be expiring until 2029! talk about a winner. I like this one.

Recs

0
Member Avatar dreamjob (86.81) Submitted: 4/2/2015 10:38:38 PM : Outperform Start Price: $98.68 GILD Score: +10.91

This is so cheap it's just about a no-brainer. I know the market is freaking out about all the competition from other drug makers, but Gilead is still a key player and has not lost the war. Enormous earning power and a very affordable price tag.

Featured Broker Partners


Advertisement